Tags

Type your tag names separated by a space and hit enter

[Study of propoleum dosage in Peyronie's disease].
Arch Esp Urol. 2003 Sep; 56(7):814-9.AE

Abstract

OBJECTIVES

To determine the optimal dose for propoleum caps in Peyronie's disease.

METHODS

We evaluated two groups of 17 patients each, analyzing pain and plaque size on physical and ultrasound examination, before and after treatment. Group A patients received caps with 300 mg of propoleum powder daily for six months, and Group B 900 mg.

RESULTS

Predominant ages were between 41 and 70 years. More than half the patients in group A had pain; more than half the patients in group B did not have pain; considering both groups there were more patients without pain. Physical reduction of the plaque: Group A: 0.6 cm, Group B: 0.8 cm. Ultrasound reduction of the plaque: Group A: 1.3 cm, Group B: 0.8 cm. In the higher dose group (B) clinical and ultrasound improvement started earlier. 79.4% of the treated patients evaluated preferred improvement or slight improvement, being this result statistically significant.

CONCLUSIONS

Pain is not always an accompanying symptom in Peyronie's disease. Both doses administered reduced the size of the plaque, but the higher one has an earlier improvement. We may consider propoleum administered in this way another treatment option for this disease, with good results and low cost.

Authors+Show Affiliations

Servicio de Urología, Hospital Docente Quirúrgico Freyre de Andrade, La Habana, Cuba. malem@infomed.sld.cuNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

spa

PubMed ID

14595886

Citation

Lemourt Oliva, Manuel, et al. "[Study of Propoleum Dosage in Peyronie's Disease]." Archivos Espanoles De Urologia, vol. 56, no. 7, 2003, pp. 814-9.
Lemourt Oliva M, Rodríguez Barroso A, Bordonado Ramírez R, et al. [Study of propoleum dosage in Peyronie's disease]. Arch Esp Urol. 2003;56(7):814-9.
Lemourt Oliva, M., Rodríguez Barroso, A., Bordonado Ramírez, R., González Oramas, E., & Molina Castillo, F. (2003). [Study of propoleum dosage in Peyronie's disease]. Archivos Espanoles De Urologia, 56(7), 814-9.
Lemourt Oliva M, et al. [Study of Propoleum Dosage in Peyronie's Disease]. Arch Esp Urol. 2003;56(7):814-9. PubMed PMID: 14595886.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Study of propoleum dosage in Peyronie's disease]. AU - Lemourt Oliva,Manuel, AU - Rodríguez Barroso,Ada, AU - Bordonado Ramírez,Rafaela, AU - González Oramas,Elizabeth, AU - Molina Castillo,Félix, PY - 2003/11/5/pubmed PY - 2004/1/7/medline PY - 2003/11/5/entrez SP - 814 EP - 9 JF - Archivos espanoles de urologia JO - Arch Esp Urol VL - 56 IS - 7 N2 - OBJECTIVES: To determine the optimal dose for propoleum caps in Peyronie's disease. METHODS: We evaluated two groups of 17 patients each, analyzing pain and plaque size on physical and ultrasound examination, before and after treatment. Group A patients received caps with 300 mg of propoleum powder daily for six months, and Group B 900 mg. RESULTS: Predominant ages were between 41 and 70 years. More than half the patients in group A had pain; more than half the patients in group B did not have pain; considering both groups there were more patients without pain. Physical reduction of the plaque: Group A: 0.6 cm, Group B: 0.8 cm. Ultrasound reduction of the plaque: Group A: 1.3 cm, Group B: 0.8 cm. In the higher dose group (B) clinical and ultrasound improvement started earlier. 79.4% of the treated patients evaluated preferred improvement or slight improvement, being this result statistically significant. CONCLUSIONS: Pain is not always an accompanying symptom in Peyronie's disease. Both doses administered reduced the size of the plaque, but the higher one has an earlier improvement. We may consider propoleum administered in this way another treatment option for this disease, with good results and low cost. SN - 0004-0614 UR - https://wwww.unboundmedicine.com/medline/citation/14595886/[Study_of_propoleum_dosage_in_Peyronie's_disease]_ L2 - http://www.aeurologia.com/articulo_prod.php?id_art=5998536333930 DB - PRIME DP - Unbound Medicine ER -